Last reviewed · How we verify
Late-onset Pompe disease
Approved treatments
- Pombiliti · Amicus Therapeutics Europe Limited
Pombiliti works by replacing the deficient acid alpha-glucosidase enzyme in patients with Late-onset Pompe disease. - NEXVIAZYME · GENZYME CORP
- POMBILITI · AMICUS THERAP US
- Neogaa · Sanofi
AVALGLUCOSIDASE ALFA breaks down glycogen in lysosomes to treat Pompe disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Late-onset Pompe disease patent landscape — cliff calendar, originator estates, attackable patents
- Late-onset Pompe disease treatment landscape brief
- Late-onset Pompe disease treatment updates RSS
Frequently asked questions about Late-onset Pompe disease
What drugs treat Late-onset Pompe disease?
Tracked treatments include Pombiliti, NEXVIAZYME, POMBILITI, Neogaa.
What is the treatment for Late-onset Pompe disease?
Standard treatment for Late-onset Pompe disease includes Pombiliti, NEXVIAZYME, POMBILITI, Neogaa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Late-onset Pompe disease patent cliff · Late-onset Pompe disease CI report
- Treatment: Pombiliti · Amicus Therapeutics Europe Limited
- Treatment: NEXVIAZYME · GENZYME CORP
- Treatment: POMBILITI · AMICUS THERAP US
- Treatment: Neogaa · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing